ArticleInternational journal of clinical oncology2026
Clinical value of prostate-specific antigen halving time as a predictor of response to first-line systemic treatment for synchronous metastatic castration-sensitive prostate cancer.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo address the challenge of early predicting systemic treatment response in metastatic castration-sensitive prostate cancer (mCSPC), this study evaluated the predictive value of prostate-specific antigen halving time (PSAHT) as a biomarker.
methodsWe retrospectively analyzed data for 719 patients with de novo mCSPC, of whom 495 received androgen deprivation therapy alone or combined androgen blockade (the ADT/CAB cohort) and 224 received ADT combined with an androgen receptor signaling inhibitor or docetaxel (the upfront cohort). PSAHT was estimated using log-transformed PSA values at baseline and 1 and 3 months later using a linear mixed-effects model. Individual slopes were used to calculate PSAHT, defined as log(2)/|slope|. Each cohort was divided into short and long PSAHT groups based on the median PSAHT. The primary endpoint was time to castration-resistant prostate cancer (CRPC). A multivariable Cox proportional hazards model was used to assess PSAHT as a predictive biomarker.
resultsLog-transformed PSA decreased in a linear manner for up to 3 months post-treatment initiation and then plateaued. Median PSAHT was 0.47 months in the ADT/CAB cohort and 0.41 months in the upfront cohort. CRPC-free survival was more favorable in the short PSAHT group in both cohorts (ADT/CAB, 21.7 months vs. 15.9 months, P = 0.03; upfront, not reached vs. 27.1 months, P < 0.01). In multivariable Cox proportional hazards analysis, PSAHT was associated with time to CRPC in both cohorts.
conclusionPSAHT may have modest prognostic value in de novo mCSPC, although further validation is required.
Indexed as
Identifiers
42640376What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.